CG Oncology Inc
CGON
查看详细走势图
50.360USD
+1.160+2.36%
收盘 02/06, 16:00（美东）报价延迟15分钟
3.94B总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+2.36%
5天
-3.25%
1月
+18.63%
6月
+106.82%
今年开始到现在
+21.29%
1年
+74.32%
查看详细走势图
TradingKey CG Oncology Inc股票评分
单位: USD 更新时间: 2026-02-06操作建议
CG Oncology Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名36/392位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价81.00。中期看，股价处于上升通道。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
CG Oncology Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
CG Oncology Inc亮点
亮点风险
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
业绩高增长
公司营业收入稳步增长，连续3年增长496.34%
业绩增长期
公司处于发展阶段，最新年度总收入1.14M美元
利润高增长
公司净利润处于行业前列，最新年度总收入1.14M美元
估值合理
公司最新PE估值-24.65，处于3年历史合理位
机构加仓
最新机构持股88.33M股，环比增加0.51%
史蒂文·科恩持仓
明星投资者史蒂文·科恩持仓，最新持仓市值1.52M
分析师目标
根据
15
位分析师
买入
评级
81.000
目标均价
+55.83%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
CG Oncology Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CG Oncology Inc简介
CG Oncology, Inc. is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The Company’s product candidate, cretostimogene grenadenorepvec (cretostimogene) is in clinical development for the treatment of patients with non-muscle invasive bladder cancer (NMIBC). Its BOND-003 is in Phase III clinical trial, which is designed to assess the safety and efficacy of cretostimogene in high-risk Bacillus Calmette Guerin (BCG)-unresponsive NMIBC when administered as a monotherapy. Its CORE-001 is a Phase II single-arm, open-label clinical trial of cretostimogene administered with BCG-unresponsive NMIBC. Its portfolio also includes PIVOT-006, a Phase III trial to assess the safety and efficacy of adjuvant cretostimogene when administered as monotherapy to patients with intermediate-risk NMIBC following transurethral resection of the bladder tumor (TURBT).
公司代码CGON
公司CG Oncology Inc
CEOKuan (Arthur)
网址https://www.cgoncology.com/
相关品种
